# US 2025/0147046 A1 · New method for identifying herv-derived epitopes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0147046 A1
- Document ID: US20250147046A1
- Status: Published application
- Kind: A1
- Application number: 18/832,712
- Filed: 2023-01-25
- Published: 2025-05-08
- Earliest claimed: 2022-01-25
- Assignees: Ervimmune; Centre Leon Berard; Universite Claude Bernard Lyon 1; Centre National De La Recherche Scientifique; Institut National De La Sante Et De La Recherche Medicale (Inserm)
- Applicants: Ervimmune; Centre Leon Berard; Universite Claude Bernard Lyon 1; Centre National De La Recherche Scientifique; Institut National De La Sante Et De La Recherche Medicale (Inserm)
- Inventors: Stéphane DEPIL; Vincent ALCAZER
- Web page: https://patentgrep.com/patent/US20250147046A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 38/162: {from virus}
- A61K 39/12: Viral antigens
- A61P 35/00: Antineoplastic agents
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/005: from viruses
- C07K 14/15: Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- G16B 30/10: Sequence alignment; Homology search
- A61K 2039/572: {cytotoxic response}
- A61K 2039/585: {wherein the target is cancer}
- C12N 2510/00: Genetically modified cells
- C12N 2740/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

Methods for identifying HERV-derived T cell epitopes associated with cancer, and peptides that are or that include epitopes identified by the methods, expression vectors encoding the peptides, cytotoxic T lymphocytes (CTLs) of a subject treated with the peptides or vectors and engineered T cells expressing T-cell receptors recognizing the peptides. Also, the peptides, expression vectors, CTLs or engineered T cells as a vaccine or a medicament, and in particular the use of the peptides, expression vectors, CTLs or engineered T cells for use in preventing or treating cancer in a subject in need thereof.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method for identifying Human endogenous retroviruses (HERVs)-derived T cells epitopes associated with at least one cancer, wherein said method comprises the following steps:
(a) identifying HERVs associated with at least one cancer, and
(b) selecting T cell epitopes among the HERVs identified in the previous step, and
wherein said method further comprises at least one of the following steps:
(i) selecting HERVs associated with a cytotoxic T cells response among the cancer-associated HERVs identified in step (a), said step being between the step (a) and the step (b), and/or
(ii) assessing the expression at the protein or peptide level of the HERVs-derived T cells epitopes identified in step (b) in tumor samples, said step being after the step (b).

### Claim 17 (depends on 16)

The method according to claim 16, wherein said method comprises the two steps (i) and (ii).

### Claim 18 (depends on 16)

The method according to claim 16, wherein steps (a), (b), (i) and (ii) are in silico steps, or wherein steps (a), (b) and (i) are in silico steps and step (ii) is an in vitro step.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the step (a) comprises the step of comparing HERVs expression in tumor and in normal samples.

### Claim 20 (depends on 16)

The method according to claim 16, wherein the step (b) comprises the step of aligning the sequences of the HERVs identified in the previous step with HERV proteins.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the step (b) further comprises the step of predicting the binding of the sequences sharing at least 70, 75, 80, 85, 90, 95, 96, 97, 98, 99% or more identity with HERV proteins to MHC class I molecules.

### Claim 22 (depends on 16)

The method according to claim 16, wherein the association of the cancer-associated HERVs with a cytotoxic T cells response in the step (i) is assessed by the association of each HERV with at least one CD4 or CD8 T cell signature, the association of each HERV with a function signature being either interferon (IFN)-γ signature or cytolytic activity, and the absence of expression of each HERV in normal purified T or NK cells.

### Claim 23 (depends on 22)

The method according to claim 22, wherein said association is assessed by a machine learning-based approach.

### Claim 24 (depends on 16)

The method according to claim 16, wherein said method further comprises, after the step (b) or before the step (ii), a step of selecting epitopes among the most shared epitopes in the cancer-associated HERVs identified in step (a).

### Claim 25 (depends on 16)

The method according to claim 16, wherein said method further comprises, after the step (b) or after the step (ii), a step of aligning the HERVs-derived T cell epitopes with human proteome.

### Claim 26 (depends on 16)

A peptide comprising or consisting of an epitope identified by the method according to claim 16.

### Claim 27

A peptide comprising or consisting of an epitope having a sequence selected from the group comprising or consisting of RMLTDLRAV (SEQ ID NO: 3), LMAQAITGV (SEQ ID NO: 11), VLQDFDQPI (SEQ ID NO: 13), MLLAALMIV (SEQ ID NO: 15) and YIDDILCAA (SEQ ID NO: 16).

### Claim 28 (depends on 27)

An expression vector inducing expression of one or more peptide(s) according to claim 27.

### Claim 29 (depends on 27)

A cytotoxic T-lymphocyte of a subject treated with one or more peptide(s) according to claim 27, or one or more expression vector(s) inducing expression of said one or more peptide(s).

### Claim 30 (depends on 27)

An engineered T cell expressing a T-cell receptor recognizing a peptide according to claim 27.

### Claim 31 (depends on 27)

A method for treating or preventing a cancer in a subject in need thereof, wherein said method comprises the administration of:
one or more peptide(s) according to claim 27,
one or more expression vector(s) inducing expression of said one or more peptide(s),
one or more cytotoxic T-lymphocyte(s) of a subject treated with said one or more peptide(s), or with said one or more expression vector(s), or
one or more engineered T cell(s) recognizing said one or more peptide(s).

### Claim 32 (depends on 31)

The method according to claim 31, wherein said cancer is selected from the group comprising or consisting of breast cancer, ovarian cancer, melanoma, sarcoma, teratocarcinoma, bladder cancer, lung cancer, head and neck cancer, colorectal cancer, glioblastoma, leukemias, lymphomas and other solid tumors and hematological malignancies.

### Claim 33 (depends on 32)

The method according to claim 32, wherein the breast cancer is triple negative breast cancer.

### Claim 34 (depends on 32)

The method according to claim 32, wherein the lung cancer is non-small cell lung carcinoma or small cell lung carcinoma.
